APA (7th ed.) Citation

SC, N., JH, M., SS, P., Y, K., JH, L., HS, E., . . . S, C. (2025). Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma. International journal of hematology, 121(5), 670. https://doi.org/10.1007/s12185-025-03927-z

Chicago Style (17th ed.) Citation

SC, Ng, et al. "Real-world Effectiveness of Ixazomib, Lenalidomide and Dexamethasone in Asians with Relapsed/refractory Multiple Myeloma." International Journal of Hematology 121, no. 5 (2025): 670. https://doi.org/10.1007/s12185-025-03927-z.

MLA (9th ed.) Citation

SC, Ng, et al. "Real-world Effectiveness of Ixazomib, Lenalidomide and Dexamethasone in Asians with Relapsed/refractory Multiple Myeloma." International Journal of Hematology, vol. 121, no. 5, 2025, p. 670, https://doi.org/10.1007/s12185-025-03927-z.